Cargando…
Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)
Autores principales: | Lum, Lawrence G, Choi, Minsig, Thakur, Archana, Deol, Abhinav, Fields, Kristie, Tomaszewski, Elyse, Schalk, Dana, Kondadasule, Vidya, Dyson, Greg, Mahaseth, Hemchandra, Philip, Philip, Shields, Anthony |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645487/ http://dx.doi.org/10.1186/2051-1426-3-S2-P55 |
Ejemplares similares
-
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
por: Lum, Lawrence G., et al.
Publicado: (2020) -
Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
por: Yano, Hiroshi, et al.
Publicado: (2014) -
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
por: Lum, Lawrence G., et al.
Publicado: (2021) -
Vaccination with bispecific antibody armed T cells (BATC) in metastatic breast cancer patients and transfer of anti-breast cancer immunity in primed T cells after stem cell transplant: a proof of principle study
por: Thakur, Archana, et al.
Publicado: (2015) -
Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness
por: Thakur, Archana, et al.
Publicado: (2021)